In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma ...

In the EFS analysis, axi-cel showed superiority to the standard of care, with a median EFS of 8.3 months vs 2.0 months in the standard-of-care cohort at a median follow-up of 24.9 months.

In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti ...

Axicabtagene ciloleucel (Yescarta; Kite Pharma/Gilead Sciences) — also known as axi-cel — is an autologous, gene-edited chimeric antigen receptor T-cell therapy that targets CD19 on the ...